Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 265 matching trials from the live ClinicalTrials.gov search.
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Biological · Other
Lead sponsor
Meissa Vaccines, Inc.
Industry
Eligibility
6 Months to 36 Months
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
Conditions
RSV Infection
Interventions
Candidate vaccine, SCB-1019T, AREXVY, placebo
Biological · Other
Lead sponsor
Clover Biopharmaceuticals USA, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Conditions
Infection
Interventions
ribavirin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • St Louis, Missouri + 1 more
Conditions
Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
Interventions
RI-001
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Denver, Colorado • Hialeah, Florida • Savannah, Georgia + 8 more
Conditions
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions
RSV preF-based Vaccine, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
Conditions
Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
3
States / cities
Stockbridge, Georgia • Lenexa, Kansas • Seattle, Washington
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Conditions
RSV Infection
Interventions
EDP-938, Fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Healthy
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Year to 9 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
11,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 6 Months
Enrollment
1,177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
107
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, Normal Saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Conditions
Respiratory Syncytial Virus Infection
Interventions
Abrysvo, Beyfortus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
Conditions
RSV Infection
Interventions
EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Respiratory Infections, Bronchiolitis, Pneumonia, Apnea
Interventions
Emergency Dept. Subjects with LRI or Apnea
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Day to 12 Months
Enrollment
2,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Sylmar, California • Denver, Colorado + 29 more
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF (Regimen A), RSVpreF (Regimen B)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
13
States / cities
Tempe, Arizona • Dublin, California • Doral, Florida + 10 more
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more